PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 621-623
DOI: 10.4103/ijmpo.ijmpo_60_20
Practitioner Section

Drawback of Chimerism Analysis by XY-Fluorescence In Situ Hybridization: Deception of a Relapse

D VS Kiran Kumar
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Jayachandran Perumal Kalaiyarasi
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Chimerism is monitored by various methods in posttransplant patients. Interphase fluorescence in situ hybridization (FISH) for XY (sex) chromosomes is one of the methods commonly employed. It is a sensitive method in terms of the number of cells analyzed. Chimerism testing is done to detect graft rejection/failure which eventually may be a sign of relapse of the malignancy. The relapse of the disease initially happens in the marrow and then spreads to the peripheral blood. Hence, performing chimerism by XY-FISH in the peripheral blood may miss an early relapse. Here, we present one such case where there was 98% donor chimerism with the evidence of relapse in the bone marrow with all recipient metaphases in the bone marrow by conventional cytogenetics.

Keywords

Chimerism - posttransplant monitoring - XY-fluorescence in situ hybridization


Publikationsverlauf

Eingereicht: 13. Februar 2020

Angenommen: 07. April 2020

Artikel online veröffentlicht:
17. Mai 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M. et al. Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant?. PLOS One 2016; 11: e0154737
    CrossrefPubMedSuche in Google Scholar
  • 2 Balon J, Hałaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A. et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant 2005; 35: 1083-8
    CrossrefPubMedSuche in Google Scholar
  • 3 Van Deerlin VM, Reshef R. Chimerism testing in allogeneic hematopoietic stem cell transplantation. In: Leonard DG. editor Molecular Pathology in Clinical Practice. Cham: Springer International Publishing; 2016: 823-48
    CrossrefSuche in Google Scholar
  • 4 Koldehoff M, Steckel NK, Hlinka M, Beelen DW, Elmaagacli AH. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol 2006; 81: 735-46
    CrossrefPubMedSuche in Google Scholar
  • 5 He R, Wiktor AE, Durnick DK, Kurtin PJ, Van Dyke DL, Tefferi A. et al. Bone Marrow conventional karyotyping and fluorescence in situ hybridization: Defining an effective utilization strategy for evaluation of myelodysplastic syndromes. Am J Clin Pathol 2016; 146: 86-94
    CrossrefPubMedSuche in Google Scholar
  • 6 Díez-Martín JL, Llamas P, Gosálvez J, López-Fernández C, Polo N, de la Fuente MS. et al. Conventional cytogenetics and FISH evaluation of chimerism after sex-mismatched bone marrow transplantation (BMT) and donor leukocyte infusion (DLI). Haematologica 1998; 83: 408-15
    PubMedSuche in Google Scholar